FDA Approves New Hydrogel System for Peripheral Arterial Bleeds

The U.S. Food and Drug Administration (FDA) has approved the Embrace Hydrogel Embolic System for treating peripheral arterial bleeds in vessels 6 mm or less. This medical device utilizes a water-based polyethylene glycol hydrogel to create sustained vessel occlusion, offering a non-surgical option for managing arterial bleeding. The approval follows evidence established by the HALT clinical trial.